|
Mint Pharmaceuticals Inc, a leading Canadian-owned and operated manufacturer of high-quality, affordable generic medicines, has announced a new partnership with Bayer Canada, a global enterprise with core competencies in the life science fields of healthcare and nutrition, for distributing Adalat XL (nifedipine extended-release tablets) 30 mg tablets in Canada. This strategic collaboration has been taken place on September 3, 2025.
Adalat XL first received market authorization in Canada in 1995 and is indicated for the management of chronic stable angina and the management of mild to moderate essential hypertension.
Olenka Crewe, VP of business development & scientific affairs, Mint Pharmaceuticals, Jaiveer Singh, CEO Mint Pharmaceuticals, Viktoria Friedrich, country president and general manager, pharmaceutical division, Bayer Inc. Jennifer Lloyd, head of finance, pharmaceutical division, Bayer Inc.
"Canadian patients and healthcare professionals depend on uninterrupted access to vital medicines, and that responsibility drives everything we do at Mint," said Jaiveer Singh, chief executive officer of Mint Pharmaceuticals. "By partnering with Bayer, we are reinforcing our shared commitment to reliability, quality, and patient care. With a best-in-class supply chain built over the past 15 years, Mint is proud to bring that strength to the distribution of Adalat XL, ensuring Canadians have seamless access to this trusted therapy."
"We are excited to partner with Mint Pharmaceuticals Inc., a company known for its commitment to quality and customer service," said Viktoria Friedrich, country president and general manager at Bayer Inc., Pharmaceutical Division. "This partnership will enable us to leverage Mint's extensive distribution network and expertise in the Canadian market, ensuring that Adalat XL remains readily available to those who need it."
Adalat XL (nifedipine extended-release tablets) is indicated for the management of chronic stable angina and the management of mild to moderate essential hypertension. With this new partnership, both companies aim to enhance the accessibility and availability of Adalat XL to healthcare providers and patients across Canada.
Mint Pharmaceuticals shares Bayer Canada's dedication to providing high-quality pharmaceutical products and exceptional service. The collaboration will focus on maintaining the highest standards of distribution to ensure that healthcare professionals and patients can rely on the timely availability of Adalat XL.
Mint Pharmaceuticals has built one of the strongest and most resilient pharmaceutical supply chains in the country, helping safeguard patient access by averting 23 national drug shortages across 16 essential medicines in the last decade.
In 2024, Mint launched its 100th molecule in Canada, marking a major milestone in portfolio growth. The company has been recognized by Deloitte as one of Canada's Best Managed Companies for seven consecutive years, achieving Platinum Club status in 2025, and is a member company of the Canadian Generic Pharmaceutical Association.
|